Clinical application of radiolabeled FAPIs in non-malignant lesions

VernacularTitle:放射性标记FAPIs在非恶性病变中的临床应用
Author: Xi WANG ¹ ; Wei HAN ; Zhehao LYU ; Shan LIU ; Yan WANG ; Peng FU
Author Information

1. 哈尔滨医科大学附属第一医院核医学科，哈尔滨　150001
Keywords: Antagonists and inhibitors; Membrane proteins; Fibroblasts; Trends
From: Chinese Journal of Nuclear Medicine and Molecular Imaging 2024;44(1):51-55
CountryChina
Language:Chinese
Abstract: Fibroblast activation protein inhibitor (FAPI) has been the focus of nuclear medicine since its introduction. With the in-depth study of FAPI tracer, its clinical application in various non-malignant diseases has also been gradually reported. Many studies have confirmed its uptake in a variety of non-malignant diseases, which indicate that FAPI tracers have good application prospects. This article reviews the latest research status and clinical application of radiolabeled FAPIs in cardiovascular diseases, rheumatic immune diseases, immunoglobulin (Ig)G4-related diseases, renal fibrosis and other non-malignant diseases at home and abroad.